Declaration of the End of Trial Form (cf. Section 4.2.1 of the *Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial*[1])

NOTIFICATION OF THE END OF A CLINICAL TRIAL OF A MEDICINE FOR HUMAN USE TO THE COMPETENT AUTHORITY AND THE ETHICS COMMITTEE

For official use

Date of receipt :	Competent authority registration number : Ethics committee registration number:

To be filled in by the applicant

A MEMBER STATE IN WHICH THE DECLARATION IS BEING MADE : The Netherlands

B TRIAL IDENTIFICATION

B.1 EudraCT number : 2018-004233-33
B.2 Sponsor's protocol code number: CMHS552A12101, v02, 28Jul2020
B.3 Full title of the trial : A first-in-human, randomized, subject-blinded, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of MHS552 in healthy volunteers

C APPLICANT IDENTIFICATION (please tick the appropriate box)

C.1	**DECLARATION FOR THE COMPETENT AUTHORITY**	☑
C.1.1	Sponsor	☐
C.1.2	Legal representative of the sponsor	☐
C.1.3	Person or organisation authorised by the sponsor to make the application.	☑
C.1.4	**Complete below**:	
C.1.4.1	Organisation : Parexel International Romania s.r.l.	
C.1.4.2	Name of person to contact : 5.1.2.e	
C.1.4.3	Address : Metropolis Center, 89-97 Grigore Alexandrescu St., 010624 Bucharest, Romania	
C.1.4.4	Telephone number : +40 5.1.2.e	
C.1.4.5	Fax number : +40 5.1.2.e	
C.1.4.6	E-mail : 5.1.2.e @novartis.com	

C.2	**DECLARATION FOR THE ETHICS COMMITTEE**	☐
C.2.1	Sponsor	☐
C.2.2	Legal representative of the sponsor	☐
C.2.3	Person or organisation authorised by the sponsor to make the application.	☐
C.2.4	Investigator in charge of the application if applicable[2]:	
	• Co-ordinating investigator (for multicentre trial):	☐
	• Principal investigator (for single centre trial):	☐
C.2.5	**Complete below** :	
C.2.5.1	Organisation:	
C.2.5.2	Name :	
C.2.5.3	Address :	
C.2.5.4	Telephone number :	
C.2.5.5	Fax number :	
C.2.5.6	E-mail :	

1 OJ, C82, 30.3.2010, p. 1; hereinafter referred to as 'detailed guidance CT-1'.
2 According to national legislation.

D END OF TRIAL

D.1 Date of the end of the trial in this Member State ? [3]	yes ☑ no ☐
D.1.1. (YYYY/MM/DD): 2021/07/19	

D.2 Date of the end of the complete trial in all countries concerned by the trial? [3]	yes ☑ no ☐
D.2.1 (YYYY/MM/DD): 2021/07/19	

D.3 Is it an early termination? [4]	yes ☑ no ☐
D.3.1 If yes, give date (YYYY/MM/DD): 2021/07/19	
D.3.2 Briefly describe in an annex (free text):	
D.3.2.1 The justification for early termination of the trial; In the last planned cohort B3 (15 mg) of the single dose first-in-human study, one of the pre-specified stopping rules was met as two subjects (one in B2 (8 mg) and one in B3) developed CTCAE Grade 2 hypersensitivity-like reactions, i.e. skin rash. Therefore, a temporary halt was initiated with no further enrollment. In addition, one of these subjects later developed a Serious Adverse Event (SAE) of renal insufficiency. Both subjects have completely recovered. After a safety review, it was concluded that sufficient information was obtained in the study from the previous cohorts and the maximum tolerated dose was reached; therefore, the study is terminated early.	
D.3.2.2 Number of patients still receiving treatment at time of early termination in the MS concerned by the declaration and their proposed management; As this was a single dose FIH study, there are no subjects who are still receiving treatment and all subjects have completed their End of Study visits.	
D.3.2.3 The consequences of early termination for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product. As the early termination of the study occurred while in the last dose cohort, sufficient information on MHS552 in the earlier cohorts including reaching a maximum tolerable dose (MTD) was achieved. Overall, interim data from the FIH study shows a generally favorable safety and tolerability profile for MHS552 up to 90 ug/kg i.v. or 8 mg s.c. doses. Therefore, the pharmacokinetics, pharmacodynamics, and safety results from the FIH study will be used to determine the dose and design for the next study, and the overall risk benefit assessment remains favorable for the continued development of MHS552.	

E SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

E.1 I hereby ~~confirm that~~/confirm on behalf of the sponsor that (delete which is not applicable):

- The above information given on this declaration is correct; and
- That the clinical trial summary report will be submitted within the applicable deadlines in accordance with the applicable guidance by the Commission. [5]

E.2 APPLICANT TO THE COMPETENT AUTHORITY (as stated in C.1)	☑
E.2.1 Date : 26-Jul-2021	
E.2.2 Signature : [redacted] 5.1.2.e	
E.2.3 Print name: [redacted] 5.1.2.e	

[3] In case of a multi-country trial, if the national and global end of trial dates are different in a given Member State, the sponsor shall submit this form two times :

1) At the end of the trial in the individual Member State, section D1.1. shall be completed and submitted to the respective National Competent Authority.

2) At the global end of the trial, the sponsor shall complete section D.2.1. with the global trial end date and the completed form shall be submitted to all participating Member States in order to allow the sponsor to prepare the trial result summary within the 12-months (or 6-months in case of paediatric trials) timeframe.

If the national and global end dates coincide in a concerned Member State, the form shall be submitted only once to the National Competent Authority of this Member State with both sections D1.1. and D2.1 complete.

[4] Cf. Section 4.2. of the detailed guidance CT-1.

[5] Section 4.3. of the detailed guidance CT-1.

E.3	**APPLICANT TO THE ETHICS COMMITTEE** (as stated in C.2) **:**	☐
E.3.1	Date :	
E.3.2	Signature :	
E.3.3	Print name:	